10-Q: Hoth Therapeutics Q3 Loss Widens Amid R&D Boost, Digital Asset Strategy

Hoth Therapeutics reported a wider net loss in Q3 2025 due to increased R&D and administrative expenses, while securing additional capital through warrant exercises and an ATM offering.

Summary

• Net loss for the three months ended September 30, 2025, increased to $4.11 million, up from $2.23 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, was $9.78 million, compared to $6.09 million for the same period in 2024.
• Research and development expenses significantly increased to $1.63 million in Q3 2025 (from $0.99 million in Q3 2024) and $4.63 million for the nine months (from $2.21 million in 9M 2024), driven by HT-001 manufacturing/clinical activities and a $1.25 million patent acquisition.
• General and administrative expenses rose to $2.45 million in Q3 2025 (from $1.23 million in Q3 2024) and $5.12 million for the nine months (from $3.90 million in 9M 2024), primarily due to CEO stock compensation and increased professional fees.
• Cash and cash equivalents stood at $7.85 million as of September 30, 2025, an increase from $7.04 million at December 31, 2024.
• The company purchased $300,000 in crypto assets (Bitcoin, Ethereum, Solana) during the nine months ended September 30, 2025, which experienced an unrealized loss of $25,305.
• Net cash provided by financing activities was $8.76 million for the nine months, largely from warrant exercises ($5.63 million) and common stock issuance via an At-The-Market (ATM) offering ($3.51 million).
• An employment agreement for CEO Robb Knie was approved, setting an annual base salary of $550,000 and eligibility for an annual bonus of up to $550,000.
• A material weakness in internal control over financial reporting was identified concerning the classification of prepaid expenses and R&D expenses.

Sentiment

Score: 3

Explanation: The company reported a significantly wider net loss and increased cash burn from operations, indicating deteriorating financial performance. While it successfully raised capital through financing activities and has sufficient cash for the next 12 months, the identified material weakness in internal controls and the unrealized loss on crypto assets add concerns. The termination of a potential joint venture also reflects a setback. The increased R&D spend is necessary for a clinical-stage company but contributes to the losses.

Positives

• Cash and cash equivalents increased to $7.85 million as of September 30, 2025, from $7.04 million at December 31, 2024.
• Net cash provided by financing activities significantly increased to $8.76 million for the nine months ended September 30, 2025, compared to $3.68 million in the prior year, indicating successful capital raising efforts.
• Current cash is believed to be sufficient to fund operations for at least the next 12 months from the issuance date of these financial statements.
• Initiated a VA-backed study for GDNF as a potential new therapy for obesity and fatty liver disease, with results expected in early 2026.
• Successfully acquired patent applications for $1,250,500, enhancing the company's intellectual property portfolio.
• Net loss per common share improved to $(0.30) in Q3 2025 from $(0.32) in Q3 2024, and to $(0.74) for 9M 2025 from $(1.00) for 9M 2024, despite a larger net loss, due to a significant increase in outstanding shares.

Negatives

• Net loss widened to $4.11 million in Q3 2025 from $2.23 million in Q3 2024, and to $9.78 million for the nine months ended September 30, 2025, from $6.09 million in the prior year.
• Operating expenses increased substantially, with R&D up to $1.63 million in Q3 2025 and G&A up to $2.45 million in Q3 2025.
• Net cash used in operating activities increased to $7.65 million for the nine months ended September 30, 2025, from $4.95 million in the prior year, indicating a higher cash burn rate.
• Incurred an unrealized loss of $25,305 on crypto assets during the nine months ended September 30, 2025.
• The non-binding letter of intent with Silo Pharma, Inc. for a strategic joint venture focused on obesity and metabolic disease was mutually terminated.
• The company has an accumulated deficit of $70.2 million as of September 30, 2025, and has not generated any revenue from product sales since inception.

Risks

• The company has incurred substantial operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future, requiring significant additional capital.
• There are no assurances that the company will be successful in obtaining adequate additional financing on acceptable terms or at all, which could lead to delays, scaling back, or discontinuation of product candidate development.
• The implementation of a digital assets treasury strategy exposes the company to price volatility of digital assets.
• The availability of spot ETPs for digital assets (like Bitcoin and Ether) may adversely affect the market price of common stock as investors may choose ETPs for 'pure play' exposure, tax benefits, or regulatory exemptions.
• The emergence or growth of other digital assets (e.g., Dogecoin) could lessen demand for Bitcoin, Ethereum, and Solana, negatively impacting their prices and the company's future results.
• Digital assets held at third-party custodians (e.g., Coinbase) are subject to security breaches, cyberattacks, or loss of private keys, which could result in a partial or total loss of digital assets not covered by insurance.
• Digital assets are subject to significant legal, commercial, regulatory, and technical uncertainty, with potential new laws or changes to existing regulations adversely affecting digital asset prices and the company's ability to hold or transact them.
• A material weakness was identified in internal control over financial reporting related to the proper classification of prepaid expenses and other current assets and research and development expenses, which could lead to material misstatements in financial statements.

Future Outlook

The company anticipates increased research and development activities and general and administrative expenses in future periods as it develops existing and potentially new product candidates, incurs costs for clinical trials, manufacturing, regulatory approvals, and business development. It expects to continue incurring significant operating losses for the foreseeable future. The company believes its current cash is sufficient for at least the next 12 months but will require additional funding through strategic relationships, equity/debt financings, or grants to fully execute its development plans. Results from a VA-backed study on obesity and fatty liver disease are expected in early 2026.

Management Comments

• "We expect our research and development activities to increase as we develop our existing product candidates and potentially acquire new product candidates, reflecting increasing costs associated with... employee-related expenses... fees related to in-licensed products and technology... expenses incurred under agreements with clinical research organizations... the cost of acquiring and manufacturing clinical trial materials; and costs associated with non-clinical activities and regulatory approvals."
• "We anticipate that our general and administrative expenses will increase in future periods, reflecting continued and increasing costs associated with: support of our research and development activities; stock compensation granted to key employees and non-employees; support of business development activities; and increased professional fees and other costs associated with regulatory requirements that we are subject to."
• "We believe that our existing cash as of September 30, 2025 will enable us to fund our operating expenses and capital expenditure requirements for at least 12 months from the date that our unaudited condensed consolidated financial statements are available to be issued."
• "We will need to raise additional funding, through strategic relationships, public or private equity or debt financings, grants or other arrangements, to develop and seek regulatory approvals for our current and future product candidates."

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Hoth Therapeutics' increased R&D spending aligns with the typical trajectory of a clinical-stage company advancing its pipeline. The company's foray into digital assets, including Bitcoin, Ethereum, and Solana, is an unusual strategy for a biopharmaceutical firm, introducing exposure to a highly volatile and uncertain asset class. The mention of spot ETPs for digital assets highlights a broader market trend impacting how investors gain exposure to cryptocurrencies, which could indirectly affect the company's stock valuation if investors view it as an alternative to direct crypto exposure. The termination of the LOI with Silo Pharma suggests challenges in forming strategic partnerships in the competitive biotech landscape, while the VA collaboration indicates a focus on leveraging government-backed research for specific therapeutic areas like obesity and fatty liver disease.

Comparison to Industry Standards

• R&D Spending: Hoth Therapeutics' R&D expenses of $4.63 million for the nine months ended September 30, 2025, are typical for a clinical-stage biopharmaceutical company with multiple product candidates (HT-001, HT-KIT, HT-ALZ, BioLexa, HT-004, HT-VA). This level of investment is necessary to advance therapies through preclinical and clinical stages, comparable to other small-cap biotech firms in early to mid-stage development, such as Silo Pharma, Inc.
• Cash Burn: The net cash used in operating activities of $7.65 million for the nine months ended September 30, 2025, is a common characteristic of pre-revenue biopharmaceutical companies. This burn rate is consistent with the need to fund ongoing clinical trials, manufacturing, and general operations without significant product sales, similar to early-stage Avalo Therapeutics, Inc. or TherapeuticsMD, Inc.
• Capital Raising: The reliance on equity financing, including warrant exercises ($5.63 million) and At-The-Market (ATM) offerings ($3.51 million), is a standard practice for clinical-stage biotechs to fund operations and R&D. This is a common funding mechanism for companies that do not yet have commercialized products, similar to how companies like Cassava Sciences, Inc. or Annovis Bio, Inc. have raised capital.
• Digital Asset Strategy: The company's investment in crypto assets (Bitcoin, Ethereum, Solana) is highly unusual for a biopharmaceutical company. This strategy deviates significantly from industry norms, where capital is typically conserved or invested in low-risk, liquid assets to fund core drug development, making direct comparison to other biopharma companies difficult.
• Accumulated Deficit: An accumulated deficit of $70.2 million is typical for a clinical-stage biopharmaceutical company that has not yet brought a product to market. Companies like BrainStorm Cell Therapeutics Inc. or BioXcel Therapeutics, Inc. also carry significant accumulated deficits as they invest heavily in R&D before potential commercialization.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings and is not aware of any pending or threatened legal proceeding against it that could have a material adverse effect on its business, operating results, cash flows, or financial condition.

Related Party Transactions

• On August 28, 2025, the company issued 800,000 shares of common stock to its Chief Executive Officer as compensation under its equity incentive plan, with a total grant-date fair value of $968,000. Net of tax withholdings, 489,256 shares were issued.
• On January 14, 2025, the company issued options to its Chief Executive Officer to purchase up to 93,000 shares and to the CEO and an employee to purchase up to 77,000 shares, all at an exercise price of $1.55 per share, with an aggregate grant date fair value of $219,929.

Stakeholder Impact

• Shareholders: Experience dilution from ongoing equity issuances through the ATM agreement and warrant exercises. The increased net loss and cash burn could negatively impact share value. The material weakness in internal controls could erode investor confidence. The digital asset strategy introduces additional risk and volatility.
• Employees: The CEO received a new employment agreement with a substantial salary and bonus potential, as well as significant stock compensation, which could be positive for executive retention and morale.
• Customers (potential): Continued R&D investment in various product candidates (e.g., HT-001 for cancer side effects, HT-ALZ for Alzheimer's) indicates ongoing efforts to address unmet medical needs.
• Creditors: The company's reliance on equity financing and its accumulated deficit suggest a higher risk profile, though current cash is deemed sufficient for 12 months.
• Suppliers/Partners: The termination of the LOI with Silo Pharma indicates a potential missed opportunity for collaboration, while the VA partnership suggests new avenues for research and development.

Next Steps

• Continue development of product candidates: HT-001, HT-KIT, HT-ALZ, BioLexa, HT-004, HT-VA.
• Advance the VA-backed study for GDNF as a potential therapy for obesity and fatty liver disease, with results expected in early 2026.
• Seek additional funding through strategic relationships, public or private equity or debt financings, grants, or other arrangements.
• Implement and test the remediation plan for the identified material weakness in internal control over financial reporting.
• Evaluate various elections available under the One Big Beautiful Bill Act (OBBBA) related to IRC Section 174 capitalized R&D costs.

Key Dates

Recommendation

Hoth Therapeutics is a clinical-stage biopharmaceutical company with no revenue and a widening net loss, increasing from $6.1 million to $9.8 million year-over-year for the nine months ended September 30, 2025. The cash burn from operations has also increased significantly. While the company successfully raised capital through warrant exercises and an ATM offering, this comes at the cost of substantial shareholder dilution, with common shares outstanding nearly doubling. The identified material weakness in internal controls raises concerns about financial reporting reliability. Furthermore, the company's unusual strategy of holding volatile crypto assets introduces additional, non-core business risk, which has already resulted in an unrealized loss. Given the increased losses, high cash burn, ongoing dilution, internal control issues, and non-core asset risk, a seasoned investor would likely view this as a high-risk investment with significant downside potential in the short to medium term. The company's belief that current cash is sufficient for 12 months is a short-term positive, but the need for continuous capital raises in a challenging market for pre-revenue biotechs suggests ongoing financial pressure.

Keywords

Biopharmaceutical, Clinical-stage, Drug development, HT-001, HT-KIT, HT-ALZ, Obesity treatment, Alzheimer's disease, Cancer therapy, Atopic dermatitis, Asthma treatment, SEC filing, 10-Q, Financial results, Research and development, Digital assets, Cryptocurrency, Bitcoin, Ethereum, Solana, Capital raise, Warrants, ATM offering, Internal controls, Corporate governance